Skip to main content

Table 3 Factors associated with echocardiographic measurements at follow up based on multivariate analysis

From: Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study

Measurement

Significant factors

Estimate

Standard Error

95% CI

p

AoRD

Baseline AoRD

0.83

0.08

0.66 to 0.99

< 0.0001

Beta-blocker use - No

0.20

0.07

0.07 to 0.34

0.004

LVOT velocity

Baseline LVOT velocity

0.73

0.08

0.58 to 0.88

< 0.0001

LVEF

Baseline LVEF

0.61

0.08

0.45 to 0.77

< 0.0001

LA diameter

Baseline LA diameter

0.88

0.11

0.67 to 1.10

< 0.0001

LVESD

Baseline LVESD

0.51

0.08

0.34 to 0.67

< 0.0001

LVEDD

Baseline LVEDD

0.52

0.08

0.35 to 0.68

< 0.0001

Age

−0.01

0.005

−0.02 to − 0.0003

0.04

LV mass

Baseline LV mass

0.60

0.09

0.42 to 0.77

< 0.0001

Coronary heart disease - No

20.1

6.54

7.02 to 33.19

0.003

eGFR

−0.49

0.20

−0.89 to − 0.09

0.02

ACE inhibitor use - No

−13.2

6.26

−25.74 to −0.68

0.04

E:A

Baseline E:A

0.38

0.11

0.15 to 0.61

0.002

Diabetes - No

−0.30

0.14

− 0.58 to − 0.01

0.04

EDT

Baseline EDT

0.40

0.10

0.20 to 0.59

0.0001

Age

1.99

0.95

0.08 to 3.89

0.04

eGFR

0.93

0.38

0.17 to 1.68

0.01

RWT

Baseline RWT

0.68

0.08

0.51 to 0.84

< 0.001

Beta-Blocker use - No

−0.02

0.01

−0.04 to −0.001

0.04

ACE inhibitor use - No

−0.03

0.01

−0.06 to − 0.01

0.003

  1. Key: LVOT left ventricular outflow tract, LVEF left ventricular ejection fraction, LA left atrium, LVESD left ventricular end systolic diameter, LVEDD left ventricular end diastolic diameter, EDT E wave deceleration time, RWT relative wall thickness, CI confidence intervals, eGFR estimated glomerular filtration rate, AoRD aortic root diameter
  2. Each model included the following variables: treatment group, age, presence of diabetes, history of coronary heart disease, systolic blood pressure, diastolic blood pressure, degree of stenosis to most affected kidney, renal function using eGFR, prescription of beta-blockers and renin angiotensin blockade and the baseline ventricular measurement
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us